Correlation Between Immune Metabolism in Patients With Benzodiazepine Poisoning and Patients'Mental Disorders

December 22, 2021 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University

Correlation Between Early Neuro-immune Metabolism in Patients With Benzodiazepine Poisoning and Mental Disorders With Depression --- A Multiple Center Observational Study

High-dose benzodiazepines can inhibit the central nervous system, respiratory system and cardiovascular motor center, resulting in loss of consciousness, disappearance of reflex, respiratory inhibition, decrease of blood pressure and so on. This kind of drug acute poisoning is the most common drug poisoning in internal medicine. It has acute onset and severe symptoms. If it is not treated properly in time, it can be life-threatening. At present, the research on the accumulation and metabolic state caused by benzodiazepine poisoning is not sufficient; at the same time, the changes of neuroendocrine metabolism and immune function of patients with neuroendocrine metabolism and immune function need to be further explored. Therefore, the main purpose of this study is to analyze the effects of neuroendocrine metabolism and immune function on organ function and mental state in patients with benzodiazepine poisoning.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Benzodiazepines are the first choice for clinical anti-anxiety, sedation and hypnosis, as well as anticonvulsant, antiepileptic and central muscle relaxation. Commonly used are diazepam (diazepam), nitro diazepam, clonazepam, alprazolam, triazolam and so on. The drug itself is an inhibitor of the central nervous system, which has a high selectivity for the inhibition of the central nervous system, mainly inhibiting the limbic system of the brain and less inhibitory effect on the reticular ascending activation system. It mainly acts on the synaptic sites of GABA-Ergic nerve endings in the central nervous system. It enhances the affinity between GABA and its receptors by binding to benzodiazepine receptors, thus increasing the open frequency of Cl- channels coupled with GABA receptors and exerting an inhibitory effect. High-dose benzodiazepines can inhibit the central nervous system, respiratory system and cardiovascular motor center, resulting in loss of consciousness, disappearance of reflex, respiratory inhibition, decrease of blood pressure and so on. This kind of drug acute poisoning is the most common drug poisoning in internal medicine. It has acute onset and severe symptoms. If it is not treated properly in time, it can be life-threatening. At present, the research on the accumulation and metabolic state caused by benzodiazepine poisoning is not sufficient; at the same time, the changes of neuroendocrine metabolism and immune function of patients with neuroendocrine metabolism and immune function need to be further explored. Therefore, the main purpose of this study is to analyze the effects of neuroendocrine metabolism and immune function on organ function and mental state in patients with benzodiazepine poisoning.

Study Type

Observational

Enrollment (Anticipated)

30

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

posioning with Benzodiazepine along with at least one organ dysfucntion

Description

Inclusion Criteria:

Benzodiazepine poisoning Within 6 hours, at least one target organ dysfunction. No bad habits (drug use, alcohol addiction)

Exclusion Criteria:

Refusal to join this study Lack of information/incompleteness Vulnerable groups such as pregnant women, incapable of civil conduct and indeterminate agent consent Chronic multiple organ dysfunction Tumors, blood system diseases, various systemic immune diseases Various infectious diseases (various hepatitis, tuberculosis, AIDS)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time interval
Time Frame: at admittion
Interval from benzodiazepine poisoning to emergency pre-examination
at admittion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

February 1, 2022

Primary Completion (Anticipated)

June 1, 2022

Study Completion (Anticipated)

December 1, 2022

Study Registration Dates

First Submitted

December 22, 2021

First Submitted That Met QC Criteria

December 22, 2021

First Posted (Actual)

January 11, 2022

Study Record Updates

Last Update Posted (Actual)

January 11, 2022

Last Update Submitted That Met QC Criteria

December 22, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021-1069

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe